NCT01847430View on ClinicalTrials.gov

Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder

PHASE4CompletedINTERVENTIONAL
Enrollment

303

Participants

Timeline

Start Date

July 19, 2013

Primary Completion Date

February 21, 2014

Study Completion Date

February 21, 2014

Conditions
Hepatitis B
Interventions
BIOLOGICAL

Engerix™-B Kinder

Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.

Trial Locations (10)

13055

GSK Investigational Site, Berlin

24534

GSK Investigational Site, Neumünster

24937

GSK Investigational Site, Flensburg

47574

GSK Investigational Site, Goch

67227

GSK Investigational Site, Frankenthal

77694

GSK Investigational Site, Kehl

78532

GSK Investigational Site, Tuttlingen

85551

GSK Investigational Site, Kirchheim

95463

GSK Investigational Site, Bindlach

04178

GSK Investigational Site, Leipzig

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01847430 - Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder | Biotech Hunter | Biotech Hunter